细菌细菌 (BG01-4TM) 改善了自报告的便秘,消化不良和腹的症状:一期1/2A随机对照试验
Craig Patch1,2, Alan J Pearce1, Mek Cheng2
1School Allied Health, Human Services and Sport, Melbourne 3086, Australia.
Nutrients
|November 14, 2023
概括
这项研究发现,失活的Bacillus subtilis (BG01-4TM) 改善了功能性胃肠道疾病患者的便秘和相关的胃肠道症状. 建议进行进一步的研究来证实这些发现.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 营养科学 营养科学
背景情况:
- 功能性胃肠道疾病 (FGIDs) 是普遍存在的,并且难以管理.
- 益生菌越来越多地被认为是它们在调节胃肠道健康方面的作用.
- 一种富含分支链脂肪酸 (BCFA) 的非活化细菌 Bacillus subtilis (BG01-4TM) 的专有菌株被研究用于FGID治疗.
研究的目的:
- 评估BG01-4TM在治疗自我报告的FGID治疗中的疗效.
- 用GSRS评估BG01-4TM对特定胃肠道症状的影响.
- 在一项随机对照试验中,比较BG01-4TM与安慰剂的影响.
主要方法:
- 一个双盲,随机对照试验与67名参与者进行.
- 参与者接受了BG01-4TM (n=34) 或安慰剂 (n=33) 四周.
- 胃肠道症状评分表 (GSRS) 在基线,两周和四周进行了管理.
主要成果:
- 在四周后,BG01-4TM显著改善了便秘,与安慰剂 (15%) 相比,便秘率提高了33%.
- 总GSRS得分和腹症状在两组都显著改善,实验组分别改善了32%和20%.
- 探索性分析显示,与安慰剂相比,BG01-4TM组的消化不良 (11%) 和消化不良 (10%) 显著改善.
结论:
- 失活的细菌细菌 (BG01-4TM) 显示出缓解FGID特异性症状的潜力,特别是便秘.
- 该干预措施在改善相关的胃肠道功能障碍方面表现有希望.
- 需要进行更长期的研究来验证这些初步发现,并确认BG01-4TM的治疗益处.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
01:29Bacterial Flora of the Large Intestine
477
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
477
01:17Irritable Bowel Syndrome I: Introduction
281
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
281
01:17Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
166
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
166
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
214
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
214